Diacylglycerol kinases (DGKs) metabolize diacylglycerol to phosphatidic acid. In T lymphocytes, DGKα acts as a negative regulator of TCR signaling by decreasing diacylglycerol levels and inducing anergy. In this study, we show that upon costimulation of the TCR with CD28 or signaling lymphocyte activation molecule (SLAM), DGKα, but not DGKζ, exits from the nucleus and undergoes rapid negative regulation of its enzymatic activity. Inhibition of DGKα is dependent on the expression of SAP, an adaptor protein mutated in X-linked lymphoproliferative disease, which is essential for SLAM-mediated signaling and contributes to TCR/CD28-induced signaling and T cell activation. Accordingly, overexpression of SAP is sufficient to inhibit DGKα, whereas SAP mutants unable to bind either phospho-tyrosine residues or SH3 domain are ineffective. Moreover, phospholipase C activity and calcium, but not Src-family tyrosine kinases, are also required for negative regulation of DGKα. Finally, inhibi...
I
n T lymphocytes, engagement of the TCR by specific Ags, along with stimulation by costimulatory receptors such as CD28, leads to T cell activation, cytokine production, and differentiation. Moreover, several other receptors influence cell activation by quantitatively or qualitatively modifying immunoreceptor-derived signals. Conversely, stimulation via the TCR alone, although partially activating intracellular signaling pathways, is not sufficient to induce effector functions such as cytokine production and proliferation (1) .
Signaling lymphocyte activation molecule (SLAM; CD150) is a homotypic transmembrane receptor expressed in T and B lymphocytes, dendritic cells, and monocytes (2) . Upon engagement, SLAM undergoes a conformational change leading to Fyn-mediated tyrosine phosphorylation and activation of several signaling pathways that modulate TCR-induced responses (2) . Fyn recruitment to the activated SLAM is mediated by SAP, an adaptor protein comprising a single SH2 domain and a SH3 domain-binding sequence (3) . In humans, SAP loss-of-function mutations cause X-linked lymphoproliferative disease (XLP), an immune disorder characterized by a deregulated immune response to EBV, susceptibility to lymphoma and defective Ab production (4) . Interestingly, SAP-deficient T lymphocytes from either XLP patients or SAP knockout mice exhibit defective responses to TCR/CD28 costimulation in vitro: 1) T cells from XLP patients feature reduced ERK1/2 and NF-kB activation, decreased IL-2 production, and impaired proliferation (5); 2) CD4 + T cells from XLP patients exhibit reduced ICOS expression and IL-10 production (6); and 3) T cells from SAP knockout mice feature reduced protein kinase C (PKC)u membrane recruitment, Bcl-10 phosphorylation, and NF-kB activation, which are associated with defective IL-4 secretion and enhanced INF-g production (7) .
Ag-mediated activation of the TCR in the presence of other coactivating molecules triggers a complex signaling network leading to transcriptional activation of specific genes whose expression mediates T cell proliferation and differentiation. Activation of Ras and PKCu triggers key signaling pathways, leading, among others, to the activation of NF-AT and NF-kB and contributing to transcription of the IL-2 gene (8, 9) . In T cells, activation of Ras and PKCu is dependent on the generation of diacylglycerol (DAG) through phospholipase C (PLC)-mediated hydrolysis of phosphatidylinositol-4,5-bis-phosphate. DAG recruits RasGRP, the Ras-GEF mainly responsible for TCR-induced Ras activation, and PKCu to the plasma membrane (10, 11) . Notably, engagement of TCR in the absence of costimulation results in a weak and transient activation of both Ras and PKCu, which drives T cells into anergy, a hyporesponsive status characterized by the inability to produce IL-2 and proliferate (12, 13) .
DAG generated upon T cell activation is rapidly metabolized by DAG kinases (DGKs), a multigenic family of enzymes responsible for phosphorylation of DAG to phosphatidic acid (PA). Consistently with the crucial role of DAG signaling in T cell activation, several pieces of evidence indicate that the DGKa and DGKz isoforms, which are highly expressed in thymus and T cells, act as negative regulators of TCR signaling and immune cell function (14) . Specifically, 1) genetic deletion of DGKa and DGKz in T cells enhances TCR-induced activation of ERK1/2, resulting in defective induction of anergy (15, 16) ; 2) DGKa is strongly induced in anergic T cells (13) ; 3) overexpression of either DGKa or DGKz impairs CD3/CD28-induced activation of Ras signaling (17) (18) (19) ; 4) pharmacological inhibition of DGKs reverses the inability of anergic cells to produce IL-2 in response to TCR stimulation (13); and 5) DGKa expression is downregulated within a few hours from T cell activation (19) . Collectively, these data support the concept that second messengers signaling is highly dependent on the fine tuning of DAG synthesis and degradation rates. Although there is no evidence for regulation of DGKz upon T cell activation, TCR/CD28 costimulation of T cells results in rapid and sustained recruitment of DGKa to the plasma membrane (19) , an event mediated by both Lck-dependent phosphorylation of tyrosine 335 and calcium binding to the EF hand domain of DGKa (20, 21) .
Based on the role of DGKa as a negative regulator of T cell responses, we investigated the hypothesis that, upon T cell stimulation, DGKa activity might undergo negative regulation. In this study, we show indeed that the enzymatic activity of DGKa is inhibited upon costimulation of TCR and CD28 through a SAPmediated mechanism. Moreover, we found that, in SAP-deficient cells, defective TCR/CD28 signaling and T cell activation can be partially rescued by inhibition of DGKa.
Materials and Methods

Cell culture
Jurkat A3 cells (LGC Standards) and 293FT cells (Life Technologies) were cultured, respectively, in RPMI 1640 GlutaMAX medium or DMEM GlutaMAX high glucose (Life Technologies), supplemented with 10% FBS (Life Technologies) and antibiotic-antimycotic solution (SigmaAldrich) in humidified atmosphere with 5% CO 2 . PBMCs (PBLs) were isolated by Lymphoprep gradient (Axis-Shield) of ACD (130 mM citric acid, 152 mM sodium citrate, and 112 mM glucose)-treated venous blood obtained from healthy volunteers after informed consent. Briefly, blood was layered onto Ficoll-Hypaque separating media and, after 20 min centrifugation at 300 relative centrifugal force (RCF), cells were collected, washed, and suspended in RPMI 1640 GlutaMAX medium supplemented with 10% heat-inactivated FBS and antibiotic-antimycotic solution. Monocytes were depleted by plastic adherence at 37˚C for 1 h, and the remaining PBLs were maintained for 18 h in a humidified atmosphere with 5% CO 2 before further stimulation. BI-141 TTS-SAP cells were a gift of A. Veillette (Montréal, QC, Canada).
Jurkat/SAP-short hairpin RNA (shRNA) cells were obtained by infection of Jurkat cells with lentiviruses encoding SAP-specific shRNA in pLKO.1-Puro vector (clone ID TRCN00000 82712 RNAi Consortium through Sigma-Genosys), sequence: 59-CCGGCACAAGGTACTACAGGGATAA-CTCGAGTTATCCCTGTAGTACCTTGTGTTTTTG-39.
Jurkat/control-shRNA cells were obtained by infection with lentiviruses encoding a shRNA specific for murine DGKa in pLKO.1-Puro vector (clone ID TRCN00000 24825 RNAi Consortium through Sigma-Genosys), sequence: 59-CCGGGAGCTAAGTAAGGTGGTATATCTCGAGATATAC-CACCTTACTTACTTAGCTCTTTTT-39.
Lentivirus production and Jurkat infection were carried out according to the manufacturer's instructions. Infected Jurkat cells were selected for 14 d in puromycin (1 mg/ml) and used as a bulk population in all experiments.
Reagents
The Abs used recognize the following proteins: pan-Ras (Ab-4; Merck), H-Ras (F235; Cell Signaling Technology), linker for activation of T cells (LAT; Santa Cruz Biotechnology), anti-IL-2a receptor Ab (TAC; Abcam), CD3 agonist (OKT3; provided by U. Dianzani, Novara, Italy), CD28 agonist (ANC28.1/5D10; Ancell) (except for Fig. 4D , where anti-CD28 was from BD Pharmingen), SLAM agonistic Ab (A12; BioLegend), anti-DGKz Abs (gift of M. Topham, Salt Lake City, UT), mixture of DGKa Abs used for immunoprecipitation (22) , DGKa (C-20) and PKCu (Santa Cruz Biotechnology) used for immunofluorescence, ERK1/2 and phospho-ERK1/2 from Cell Signaling Technology for Supplemental Fig. 2 and from Transduction Laboratories for Fig. 5C , SAP (FL-128; Upstate Biotechnology), a-tubulin (Sigma-Aldrich), secondary HRP-conjugated Abs (PerkinElmer), secondary FITC-conjugated Ab (Dako), and Alexa Fluor 546-phalloidin (Life Technologies). In all experiments involving stimulation with Abs, species-matched preimmune serum (Santa Cruz Biotechnology) was used for controls in equal amounts.
Inhibitors used were from Sigma-Aldrich: R59949, DGKs inhibitor; PP2, Src family inhibitor; U73122, PLC inhibitor; BAPTA-AM, cell-permeable calcium chelator; wortmannin, PI3Ks inhibitor; and IPA-3, PAK-specific inhibitor. BAPTA-AM was dissolved in water; others inhibitors were dissolved in DMSO. DMSO was always used in control samples at the same dilution as the inhibitor tested.
Expression vectors and transfections
GFP-SAP-wild type, GFP-SAP-R78A, and GFP-SAP-R55L were a gift of P. Schwartzberg (National Institutes of Health, Bethesda, MD). N-terminal yellow fluorescent protein (YFP)-DGKa was obtained by cloning DGKa in pYFP-N-DEST (Life Technologies) using the Gateway kit (Life Technologies) according to the manufacturer's instructions. pNF-AT-TA-luciferase reporter vector and pRL-TK normalization vector were from Clontech. Small interfering RNA (siRNA) and negative control siRNA were from Ambion/Life Technologies: DGKa siRNA (23) sense, 59-GGUCA-GUGAUGUCCUAAAGTT-39, antisense, 59-CUUUAGGACAUCACUG-ACCTT-39.
Transient transfections in Fig. 5D and 5E were performed using Lipofectamine 2000 reagent (Life Technologies) according to the manufacturer's instructions. Microporation of Jurkat cells for imaging experiments was performed according to the manufacturers' instructions with the Microporator MP-100 system from Digital Bio Technology (Fig. 2 , Supplemental Fig. 3B ) or with the Gene Pulser II from Bio-Rad (Fig. 5B ).
Cell stimulation, preparation of cell lysates and homogenates, immunoprecipitation, Western blotting, and DGK assay Cells (3 3 10 7 /ml) were resuspended in RPMI 1640 and incubated for the indicated time with agonist Abs or control species-matched preimmune serum at 37˚C. For immunoprecipitation, 3 3 10 7 cells were lysed in 1 ml lysis buffer A (25 mM HEPES [pH 8], 1% Nonidet P-40, 10% glycerol, 150 mM NaCl, 5 mM EDTA, 2 mM EGTA, 1 mM ZnCl 2 , 50 mM ammonium molybdate, 10 mM NaF, 1 mM sodium orthovanadate, and protease inhibitor mixture from Sigma-Aldrich). An aliquot of cell lysate was retained for Western blot analysis, and the remainder was immunoprecipitated with a mixture of anti-DGKa Abs as previously described (24) . Whole-cell homogenates were prepared by homogenizing 3 3 10 7 cells in 1 ml cold buffer B (buffer A without detergent) by 20 passages in a 23-gauge syringe. Protein concentration was determined by BCA (Pierce), and equal amounts of proteins were loaded in each lane. SDS-PAGE and Western blots were performed as described previously (25) . Western blot results were acquired with a VersaDoc system and quantified using Quantity One software (Bio-Rad).
DGKa activity in cell homogenates (25 ml) and anti-DGKa immunoprecipitates were assayed by measuring initial velocities (5 min at 30˚C) as previously described (24) . Radioactive signals were detected and quantified by GS-250 Molecular Imager and Phosphor Analyst software (Bio-Rad).
Immunofluorescence
For immunofluorescence on fixed cells with Ab stimulation, cells were seeded on poly-L-lysine-coated glass coverslips (Marienfeld) in 24-well plates for 1 h and then stimulated with 10 mg/ml agonist Abs for 1 h in the presence or absence of the indicated inhibitors. Cells were then fixed with formaldehyde and stained as previously described (26) . Confocal images were acquired with a Leica confocal microscope TSP2 (objective, 363; numerical aperture, 1.32) and analyzed with LCS confocal software (Leica).
For the immunological synapse experiments, Raji cells (used as APCs) were incubated for 2 h with 10 mg/ml staphylococcal enterotoxin E. Raji cells were washed, mixed with Jurkat control-shRNA or Jurkat SAPshRNA (1:1) for 15 min, and plated on polylysine-coated wells of diagnostic microscope slides (Erie Scientific). Cells were allowed to adhere for 15 min and then fixed in methanol at 220˚C for 10 min. Samples were then washed for 5 min in PBS and incubated with anti-PKCu Ab overnight at 4˚C. After washing in PBS, samples were incubated for 1 h at room temperature with FITC-labeled anti-goat Ab. Images were taken using an Axio Imager Z1 microscope equipped with an HBO 50-W mercury lamp for epifluorescence and with an AxioCam HR cooled charge-coupled camera (Carl Zeiss).
For live cell imaging experiments, Jurkat A3 cells, Jurkat controlshRNA, and Jurkat SAP-shRNA were microporated and serum starved in RPMI 1640 plus 0.2% BSA plus 50 mM HEPES for 2 h. Cells were seeded on glass-bottom dishes coated with poly-L-lysine or with the agonistic Ab anti-CD3, anti-CD3 plus anti-SLAM, or anti-CD3 plus anti-CD28 at the final concentration of 10 mg/ml. Confocal images were acquired at the indicated times with a Zeiss LSM 510 inverted laser scanning microscope using a C-Apochromat 363 water immersion objective lens (Carl Zeiss). Laser scanning microscope image files were processed using the Zeiss ZEN laser scanning microscope image browser software. When comparisons among images were to be made, the images were taken in identical conditions and equally manipulated using Adobe Photoshop 7.0 software (Adobe Systems).
Cell fractionation
Cells (3 3 10 7 /ml) were resuspended in RPMI 1640 and incubated for the indicated time with agonist Abs or control species-matched preimmune serum at 37˚C. Whole-cell homogenates were prepared by homogenizing 3 3 10 7 cells as described above and sonicating the homogenates for 1 min. Postnuclear and postmitochondrial fractions (obtained by 10 min centrifugation at 10,000 RCF) were further separated by ultracentrifugation (30 min at 10,0000 RCF). Supernatants (soluble cytoplasmic fraction) and pellets (insoluble membrane fraction) were collected and SDS-PAGE and Western blots were performed as described previously (25) using antiDGKa and anti-LAT Abs.
Biochemical Ras activation assays
Recombinant GST-c-Raf-RBD protein was produced in Escherichia coli as described (27) . Jurkat cells were serum deprived (2 h in RPMI 1640 supplemented with 0.2% fatty acid-free/endotoxin-low BSA and 50 mM HEPES [pH 7.5]). After stimulation, 1 ml cell suspension (10 7 cells) was lysed in 1 ml ice-cold lysis buffer (50 mM HEPES [pH 7.5], 140 mM NaCl, 5 mM MgCl 2 , 1 mM DTT, 1% Nonidet-40, protease inhibitors) supplemented with 25 mg GST-RBD protein and 100 mM GDP to quench postlytic GTP-loading and GAP-dependent Ras-bound GTP hydrolysis, respectively. Cell extracts were cleared by centrifugation and GST-RBD/ Ras-GTP complexes were collected on glutathione-Sepharose, washed once with lysis buffer, and processed for SDS-PAGE analysis.
Mammalian two hybrid system
A modified Clontech MatchMaker (BD Biosciences) mammalian two-thirdhybrid assay was used. Full-length human SAP and its point-mutated variants were cloned into the pM series vectors as GAL4-binding domain fusions.
Either full-length DGKa or the N-terminal DGKa fragment was cloned into a pVP vector to direct expression of VP16-activation domain fusion proteins. These were cotransfected into subconfluent HEK293 cells with a GAL4-luciferase reporter plasmid and a pVAX-based expression plasmid containing full-length human FynT. Luciferase activity was measured after 24 h using a commercial kit (Promega).
NF-AT assay
Jurkat cells (4 3 10 6 /ml) were cotransfected with pNF-AT-TA-luc and pRL-TK plasmids. After 48 h, cells were stimulated as indicated for 16 h.
Luciferase was assayed with a Dual-Luciferase reporter assay system (Promega) according to the manufacturer's instructions and assessed using a Victor 3 V multilabel counter (PerkinElmer). NF-AT-driven firefly luciferase activity was normalized for the reference Renilla luciferase activity to take in account differences in transfection and expression efficiency, and all values were expressed as fold increase upon unstimulated controls.
IL-2 assay
Jurkat cells (1 3 10 5 ) were plated in 100 ml medium supplemented with 10% FBS and stimulated as indicated for 72 h. IL-2 released in the media was measured by ELISA (GE Healthcare).
Statistical analysis
The data were expressed as means 6 SE. Statistical analysis was determined by a Student t test.
Results
Negative regulation of DGKa during T cell activation
Becaise DGKa negatively regulates T cell activation (17, 19) , we set out to investigate whether it is regulated in the early phase of lymphocyte activation. To this purpose, we assayed the enzymatic activity and subcellular localization of DGKa upon activation of primary lymphocytes (PBLs) and Jurkat leukemic T cells. DGKa activity was measured in vitro in the presence of exogenous substrates in anti-DGKa immunoprecipitates obtained from either control or stimulated lymphocytes. Following 15 min costimulation of PBLs with agonistic anti-CD3 and anti-CD28 Abs, the enzymatic activity of DGKa was reduced by ∼60% as compared with unstimulated cells (Fig. 1A) , without any change in DGKa protein content (Fig. 1A , lower right panel). Stimulation of PBLs with anti-CD3 Ab alone did not significantly affect DGKa activity (data not shown). Becaue activation of SLAM family receptors was reported to enhance TCR signaling (28, 29) , we investigated whether SLAM might regulate the enzymatic activity of DGKa. Indeed, 15 min costimulation of PBLs with anti-CD3 and anti-SLAM agonist Abs resulted in an even stronger inhibition of DGKa activity without affecting DGKa protein content (Fig. 1A) . We then measured DGKa activity in anti-DGKa immunoprecipitates from Jurkat leukemia cells following costimulation with anti-CD3 and either anti-CD28 or anti-SLAM agonist Abs. Similar to the data on PBLs, DGKa enzymatic activity was strongly reduced upon 15 min costimulation via the TCR and either SLAM or CD28 and lasted for at least 1 h, without changes in DGKa protein content (Fig. 1B, 1C) . Finally, to address the reported ambiguity of how anti-SLAM Abs may affect SLAM signaling, we used an alternative approach to induce SLAM signaling. We used a chimeric receptor featuring SLAM intracellular domain and the extracellular and transmembrane regions of the human IL-2 receptor a-chain coexpressed with SAP in BI-141 lymphocytes (30) . Crosslinking of the chimeric receptor with TAC triggers SLAM signaling (30) and it was sufficient to induce a strong decrease of DGKa activity without changes in DGKa protein content (Fig. 1D ). This result indicates that signals originating from the intracellular domain of SLAM lead to DGKa inhibition. Taken together, these observations indicate that upon costimulation of the TCR with either CD28 or SLAM, the enzymatic activity of DGKa undergoes a negative regulation, which likely contributes to the accumulation of DAG required for RasGRPmediated activation of Ras and full T cell activation.
To verify whether this regulation was specific to DGKa, we first examined whether anti-CD3 costimulation with either anti-CD28 or anti-SLAM Abs regulated DGKz, which, along with DGKa, is highly expressed in T cells. We observed that neither CD3/CD28 nor CD3/SLAM costimulation of T cells did affect the enzymatic activity of DGKz in anti-DGKz immunoprecipitates from either control or costimulated cells (Supplemental Fig. 1 ). These observations indicate that TCR activation specifically regulates DGKa enzymatic activity while not affecting DGKz. To verify the contribution of DGKa regulation to the total cellular DGK activity, we measured DGK activity in whole-lymphocyte homogenates using exogenous substrates. Following 15 min TCR/CD28 costimulation of either PBLs or Jurkat cells, total DGK activity was not significantly affected, even when the costimulation was sufficient to activate ERK1/2 (Supplemental Fig. 2A, 2B) . Conversely, upon 15 min TCR/SLAM costimulation, total DGK activity was significantly reduced (Supplemental Fig. 2C, 2D ). Given the specific subcellular localization of DGK isoforms, these observations suggest that DGKa inhibition does not affect the bulk of DAG metabolism while selectively promoting DAG accumulation at specific compartments.
As DGKa recruitment from the cytoplasm to the plasma membrane is highly regulated both upon growth factor stimulation of epithelial cells and TCR/CD28-mediated costimulation of lymphocytes (20, 24) , we assessed DGKa localization following costimulation of the TCR with either CD28 or SLAM. Both endogenous DGKa in CD3 + PBLs and YFP-DGKa transiently expressed in Jurkat cells localize diffusely in the nucleus and in the cytoplasm of unstimulated or TCR-stimulated cells. Upon 1 h costimulation of the TCR with either CD28 or SLAM, DGKa was almost entirely excluded from the nucleus and recruited to the cell periphery in both PBLs and Jurkat cells ( Fig. 2A, 2B , Supplemental Fig. 3A, 3B ). Whereas inhibition of DGKa enzymatic activity was an early event, starting 5 min following costimulation, reaching maximal inhibition at 15 min, and lasting up to 1 h (Fig. 1C) , translocation of DGKa became detectable 15 min after costimulation, reached its maximum at 30 min, and lasted for several hours (Fig. 2B) .
To distinguish between plasma membrane and cytoplasmic localization, we labeled plasma membrane with either K-Ras-V12/ A28 (31) or wheat germ agglutinin. Upon T cell costimulation, DGKa only partially colocalized with K-Ras-V12/A28 (Fig. 2B) or with wheat germ agglutinin (Supplemental Fig. 3B ). Accordingly, ∼10% of cytoplasmic DGKa sedimented in the 100,000 RCF fraction of CD3/CD28-costimulated Jurkat cells (Fig. 2C) . These findings indicate that, upon lymphocyte activation, DGKa undergoes both negative regulation of its enzymatic activity and translocation from the nucleus to the cell periphery, although with different kinetics.
Regulation of DGKa inhibition and recruitment to the cell periphery
We explored whether translocation to the cell periphery and negative regulation of DGKa were regulated by common signaling pathways. DGKa activity and localization are regulated by Srcmediated tyrosine phosphorylation (21, 24, 25) , calcium binding (17, 32) , and D-3 phosphoinositides (33) . Pharmacological inhibition of PLC by U73122 and calcium chelation by BAPTA-AM blunted DGKa translocation from the nucleus to the cell periphery induced by costimulation of TCR with either SLAM or CD28 ( Fig. 3A) . Interestingly, PP2-mediated inhibition of Src family tyrosine kinases (SFKs) inhibited only CD3/SLAM-induced translocation. Conversely, wortmannin did not affect DGKa localization, indicating that phosphoinositide 3-kinases are not involved (Fig. 3A) . Similarly, pharmacological inhibition of PLC and calcium signaling prevented the negative regulation of DGKa activity induced by TCR/SLAM costimulation (Fig. 3B) . These data indicate that PLC activity and calcium release mediate both inhibition of DGKa activity and its translocation to the cell periphery. Conversely, inhibition of SFKs impaired specifically negative regulation of DGKa activity and its translocation to the cell periphery induced by TCR/SLAM costimulation, but not by TCR/CD28 costimulation (Fig. 3A, 3C) , indicating that the requirement of SFKs is restricted to SLAM-induced regulation of DGKa. Despite that SAP overexpression regulates cdc42, IPA-3-mediated inhibition of PAK, a cdc42 effector, does not affect DGKa activity (Fig. 3B) .
Upon SLAM engagement, SAP mediates the recruitment of Fyn, thereby promoting tyrosine phosphorylation of SLAM and activation of its downstream signaling (34) . Thus, we investigated the role of SAP in negative regulation and membrane recruitment of DGKa. SAP expression was downregulated in Jurkat cells by lentiviral-mediated stable expression of a SAP-specific shRNA (Fig. 4A, 4B) . In SAP-deficient Jurkat cells, but not in control shRNA cells, DGKa activity was not inhibited following stimulation of TCR and SLAM (Fig. 4A) , consistent with the essential role of SAP in SLAM-induced signaling. Surprisingly, in SAPdeficient cells, DGKa activity was not inhibited by TCR/CD28 costimulation. This observation suggests that SAP is not only required for SLAM signaling, but may also play a more direct role in promoting negative regulation of DGKa enzymatic activity (Fig. 4B) . Indeed, overexpression of SAP and myc-DGKa in Jurkat cells resulted in the reduction of DGKa activity by 60% as measured in anti-myc immunoprecipitates, whereas myc-DGKa protein content was not affected (Fig. 4C) . Conversely, in the same assay SAP mutants unable to bind either SH3 domains (SAP-R78A) or both tyrosine-phosphorylated proteins and SH3 domains (SAP-R55L) (3, 35) failed to inhibit DGKa (Fig. 4C) . These findings indicate that SAP overexpression is sufficient to inhibit DGKa through a mechanism that requires SH3-binding ability of SAP.
The sequence surrounding tyrosine 335 of DGKa (SIY335PSV) features a high similarity to the SAP-SH 2 binding motif on SLAM (TIY281AQV) (36) , suggesting that DGKa might bind directly to SAP. However, we could not detect a direct physical association between SAP and DGKa in a mammalian two-hybrid assay (Supplemental Fig. 4A ) or in coimmunoprecipitation assays using transfected 293T cells (Supplemental Fig. 4B ), even when the two proteins were coexpressed with SLAM and Fyn. Taken together, these results indicate that SAP does not inhibit DGKa by directly binding to it, but through the SAP-mediated recruitment of a yet unidentified SH3-containing protein.
The role of SAP in DGKa membrane recruitment in Jurkat cells was investigated by shRNA-mediated stable knockdown of SAP. SAP silencing selectively impaired the recruitment of DGKa to the cell periphery induced by TCR/SLAM costimulation, but not by TCR/CD28 costimulation (Fig. 4D) . Similar results were obtained upon transient siRNA-mediated downregulation of SAP in Jurkat FIGURE 2. YFP-DGKa localization upon T cell stimulation. A, Jurkat A3 cells were transfected with YFP-DGKa (green) and after 24 h were serum starved for 2 h and seeded for 1 h on either poly-L-lysine, anti-CD3, anti-CD3 plus anti-SLAM, or anti-CD3 plus anti-CD28 (10 mg/ml each)-coated glassbottom dishes and microscope images were acquired. Representative images are shown along with a quantification from three independent experiments. *p , 0.0005, t test versus control. Scale bar, 5 mm. B, Jurkat A3 cells were transfected with YFP-DGKa (green) and DS-Red-K-Ras V12/A38 (red) and after 72 h were serum starved for 2 h and seeded on anti-CD3 plus anti-SLAM agonistic Ab (10 mg/ml each)-coated glass-bottom dishes and images were acquired at the indicated times. Representative images are shown. Scale bar, 5 mm. C, Jurkat A3 cells were stimulated with anti-CD3 and anti-CD28 agonistic Abs (10 mg/ml each) and homogenized 1 h later. The postnuclear and postmitochondrial fraction was separated by centrifugation (100,000 RCF) in a soluble fraction and in a membrane-associated fraction. One fiftieth of the soluble fraction and the entire membrane-associated fraction were analyzed by Western blotting for DGKa and LAT content. cells (data not shown). Thus, following engagement of the TCR and SLAM, SAP is required for DGKa enzymatic inhibition and recruitment to the cell periphery. In contrast, whereas SAP is required for TCR/CD28-induced enzymatic inhibition of DGKa, it is not essential for translocation of DGKa to the cell periphery. These findings indicate that the localization and enzymatic activity of DGKa are regulated through distinct processes and kinetics, although the mechanisms involved are still partially unknown.
Inhibition of DGKa rescues the functional defects caused by SAP deficiency in XLP
Collectively, these data demonstrate that SAP is essential for regulation of DGKa activity upon T cell activation via the TCR/ SLAM or TCR/CD28. We therefore reasoned that, similarly to SAP-deficient Jurkat cells, T cells of XLP patients lacking functional SAP might be defective in the negative regulation of DGKa, thereby contributing to the defective lymphocyte responses observed in both XLP patients and in SAP-null mice. To address this hypothesis, we first characterized the signaling capacity of SAP-deficient Jurkat cells following stimulation via the TCR and CD28. We then assessed whether pharmacological inhibition of DGKa by R59949, or its siRNA-mediated downregulation, might rescue those aberrant T cell responses.
DAG-dependent recruitment of PKCu to the plasma membrane is defective in T cells from SAP-null mice, it is potentiated upon SAP overexpression (7, 37) and it is negatively regulated by constitutive activation of DGKa (38) . Consistently, in SAP-deficient Jurkat cells, PKCu recruitment to the immune synapse with super Ag-loaded APCs was impaired (Fig. 5A ). Both pharmacological inhibition (Fig. 5A ) and siRNA-mediated silencing of DGKa (Fig. 5B) nearly completely rescued the defective translocation of PKCu to the immune synapse observed in SAP-deficient Jurkat cells, pointing to a rescue of DAG-mediated signaling.
Upon TCR/CD28 costimulation, both T cells from XLP patients and Jurkat cells made SAP-deficient by siRNA-mediated downregulation exhibit defective ERK1/2 activation (5, 39), suggesting that DAG-mediated Ras-GTP signaling is impaired. Indeed, upon TCR/CD28 costimulation, Jurkat SAP-shRNA cells showed both a decrease in ERK1/2 phosphorylation and a marked reduction of Ras-GTP loading, as measured by Ras-GTP pull-down with GST-RBD (Fig. 5C ). Pharmacological inhibition of DGKa with R59949 fully restored both ERK1/2 phosphorylation and Ras-GTP loading (Fig. 5C ). These findings confirm that SAP is required for Ras activation in human T cells and provide further support to the hypothesis that negative regulation of DGKa is a critical step in the activation of the Ras pathway downstream of TCR/CD28. Interestingly, R59949 raised basal levels of ERK1/2 phosphorylation without significantly affecting Ras-GTP loading, suggesting that under these conditions ERK1/2 phosphorylation may be enhanced through a Ras-independent mechanism, likely through DAG-dependent PKCu activation (40) .
Activation of PKCu and Ras pathways upon TCR/CD28 costimulation triggers NF-AT transcriptional activity, which plays a central role in cytokine production (8, 41) . Moreover, NF-AT is activated upon SAP overexpression in Jurkat cells (42) . Consistently, SAP downregulation in Jurkat cells impaired TCR/CD28-induced stimulation of NF-AT activity, as measured by luciferase reporter system (Fig. 5D, 5E ). In SAP-deficient cells, pharmacological inhibition of DGK with 1 mM R59949 fully restored TCR/ CD28-induced activation of NF-AT without affecting basal NF-AT activity (Fig. 5D) , whereas siRNA-mediated DGKa silencing resulted only in partial rescue (Fig. 5E ). These data suggest either that DGKa along with other R59949-sensitive DGKs mediate NF-AT activation downstream from SAP or that the low quantity of DGKa remaining after RNA interference may still transduce the signaling.
Upon T cell stimulation, activation of Ras, PKCu, and NF-AT signaling pathways leads to IL-2 production (41, 43, 44) , which has been reported to be reduced in lymphocytes from XLP patients (5) . Indeed, in Jurkat cells, shRNA-mediated SAP silencing reduced TCR/CD28-induced IL-2 secretion (Fig. 5F ). Pharmacological inhibition of DGKa by R59949 enhanced TCR/CD28-induced IL-2 production in control cells and fully rescued the defective IL-2 secretion of SAP-deficient Jurkat cells. These findings suggest that SAP-mediated negative regulation of DGKa is a key event in the modulation of T cell activation.
Discussion
In this study, we demonstrate that within minutes following costimulation of the TCR with either CD28 or SLAM, the enzymatic activity of DGKa, as assayed in immunoprecipitates in the pres-FIGURE 3. PLC and calcium mediate TCR-induced regulation of DGKa. A, Jurkat A3 cells were transfected with YFP-DGKa and after 24 h were serum starved for 2 h, seeded for 1 h on poly-L-lysine, CD3 plus SLAM, or CD3 plus CD28 agonistic Ab (10 mg/ml each)-coated glassbottom dishes in the presence or absence of the indicated inhibitors (50 mM PP2, 5 mM U73122, 10 mM BAPTA-AM, or 100 nM wortmannin) and images were acquired. The quantification of three independent experiments is shown. *p , 0.0005, t test versus control. B, Jurkat A3 cells were treated with the indicated inhibitors (10 mM PP2, 5 mM U73122, 10 mM BAPTA-AM, 10 mM IPA-3) or vehicle for 30 min before stimulation with 10 mg/ml anti-CD3 and anti-SLAM Abs. After 15 min, cells were lysed and anti-DGKa immunoprecipitates were assayed for DGK enzymatic activity. The graph shows the mean 6 SE of at least three independent experiments for each inhibitor. *p , 0.05, t test versus control. C, Jurkat A3 cells were treated with 10 mM PP2 or vehicle for 30 min before stimulation with 10 mg/ml anti-CD3 and anti-CD28 Abs. After 15 min, cells were lysed and anti-DGKa immunoprecipitates were assayed for DGK enzymatic activity. The graph shows the mean 6 SE of at least three independent experiments. *p , 0.05, t test versus control. ence of saturating DAG substrate concentration, undergoes a strong negative regulation without protein downregulation. This finding is surprising, given accumulating evidence that synthesis of PA is increased upon T cell stimulation (15, 16, 45) and that DGK activity is increased in whole-cell lysates from in vivoactivated T cells (19) . However, increased PA synthesis through DAG phosphorylation may depend on both positive regulation of one or more DGK isoforms and on increased availability of DAG, whose production by PLCg is increased upon TCR/CD28 costimulation (46) . A parallel increase of DAG and PA levels upon TCR stimulation has been indeed observed (45, 47) . Several pieces of evidence suggest that most of the PA generated upon T cell activation derives from phospholipase D2-mediated phospholipid hydrolysis and from DGKz-mediated phosphorylation of DAG, whereas deletion of DGKa does not significantly affect PA production upon T cell stimulation (15, 16, 45) . Nevertheless, recent genetic and biochemical data indicating that DGKa is a negative regulator of DAG-mediated TCR signaling (15, 17) are highly consistent with our finding that enzymatic activity of DGKa is reduced upon TCR costimulation with either CD28 or SLAM. This regulation appears to be isoform-specific, as DGKz activity is unaffected by TCR triggering (Supplemental Fig. 1) . Interestingly, the previous finding that stimulation of the sole TCR is not sufficient to promote sustained DAG signaling (48) is consistent with our observation that TCR activation in PBLs is not sufficient to inhibit DGKa activity in the absence of costimulation. Moreover, costimulation of TCR/CD28, compared with TCR alone, strongly enhances production of DAG but not of PA (15), suggesting a slowdown in the rate of DAG conversion to PA that is consistent with a negative regulation of DGK activity.
The molecular mechanisms underlying the negative regulation of DGKa have not yet been elucidated. In this study, we report that the adaptor function of SAP is required for DGKa inhibition induced by TCR costimulation with either SLAM or CD28. SAP is essential for SLAM tyrosine phosphorylation by recruiting the Src-related kinase FynT (3, 34) ; however, a growing body of evidence indicates that SAP is also involved in T cell responses to antigenic stimulation (2). Indeed, SAP binds directly to ITAM sequences of CD3z subunit (29) , whereas TCR activation promotes the recruitment of SAP and SLAM family receptors to the signalosome (28, 29, 49) . Furthermore, genetic deletion of SAP in mice results in the impairment of TCR/CD28-induced DAGmediated activation of PKCu and of downstream signaling events (7). Moreover, TCR/CD28-induced ERK1/2 activation and IL-2 production, which are both dependent on DAG-mediated activation of RasGRP, are impaired in T cells from SAP-deficient XLP patients (5) . Intriguingly, SAP is physically associated to PKCu, and it has been demonstrated that SAP overexpression, which is sufficient to inhibit DGKa, promotes PKCu recruitment to the immune synapse (37) . Finally, we and others have shown that, in Jurkat cells, SAP silencing impairs TCR-induced Ras-GTP loading, ERK1/2 activation, PKCu recruitment, NF-AT activation, and IL-2 production (5-7). Taken together, these observations suggest that, upon TCR/CD28 costimulation, SAP is required for optimal DAG signaling. The finding that SAP is required for inhibition of DGKa might provide a mechanistic link between SAP and the regulation of DAG signaling. Thus, we propose that, upon stimulation of T cells from either SAP-deficient XLP patients or SAPnull mice, DGKa may inappropriately retain a high enzymatic activity, thereby converting DAG to PA and decreasing DAG signaling.
If this hypothesis holds true, we would expect that inhibition or downregulation of DGKa would rescue, at least partially, the defective signaling of SAP-deficient T cells. Accordingly, we observed that the inhibition of DGKa enzymatic activity in SAPdeficient Jurkat cells rescued defective DAG-dependent PKCu membrane recruitment, Ras-GTP loading, ERK1/2 and NF-AT activation, and IL-2 production. These findings indicate that the excess of DGKa activity contributes to the defective signaling of SAP-deficient cells and, along with the demonstration that SAP overexpression inhibits DGKa, provide further support to the hypothesis that SAP negatively regulates DGKa. According to these findings, the negative regulation of DGKa activity represents a key event controlling the early phase of T cell activation by contributing to fine tuning of DAG levels required for appropriate signaling.
In this study, we observed that costimulation of the TCR with either SLAM or CD28 induces DGKa exit from the nucleus and accumulation in the cytoplasm with only partial localization at the plasma membrane. This finding appears to contrast previous studies reporting GFP-DGKa localization at the plasma membrane of CD3/CD28 costimulated Jurkat cells; however, according to the same authors, DGKa membrane translocation is rapid and transient and can be visualized in conditions that inhibit its relocalization to the cytoplasm (17, 21) . Moreover, DGKa plasma membrane localization was clearly induced by stronger stimuli, such as the activation of ectopically overexpressed muscarinic receptor (20, 21, 50, 51) or Ag challenge in vivo (19) . Further support to the hypothesis that enzymatic activity of DGKa regulates DAG level at the plasma membrane of T cells derives both from our finding that uncoupling of DGKa inhibition from TCR stimulation impairs PKCu recruitment to the immune synapses (Fig. 5A ) and from the observation that pharmacological inhibition of DGKa allows accumulation of DAG at the plasma membrane of T cells, thereby triggering activation of Ras signaling (52) .
Interestingly, stimulation with either SLAM or TCR alone did not induce DGKa translocation from the nucleus, indicating that the concerted signaling via both receptors is required. Moreover, the finding that SAP, which is essential for SLAM tyrosine phosphorylation and signaling, is required for translocation induced exclusively by TCR/SLAM, but not by TCR/CD28, suggests that SAP may not directly regulate DGKa subcellular localization. Additionally, the fact that upon TCR/CD28 costimulation, SAP is required for inhibition of DGKa activity, but not anti-CD28 Abs and lysed. Anti-DGKa immunoprecipitates were assayed for DGK enzymatic activity while an aliquot of whole-cell lysate was analyzed by Western blot with anti-DGKa Ab to ensure equal loading and with anti-SAP Ab to verify the downregulation of SAP expression. A representative experiment is shown together with a graph of the mean 6 SE of three independent experiments shown as percentage of control. *p , 0.05, t test versus control. C, Jurkat A3 cells were transiently cotransfected with myc-DGKa and the indicated GFP-SAP mutants. After 48 h, cells were lysed and anti-myc immunoprecipitates were assayed for DGK enzymatic activity while an aliquot of whole-cell lysate was assayed by Western blot with anti-myc and anti-SAP Abs to verify transfection efficiency. A representative experiment is shown along with a graph showing the mean 6 SE of three independent experiments shown as percentage of control. *p , 0.05, t test versus control. D, Jurkat control-shRNA and Jurkat SAP-shRNA cells were transfected with YFP-DGKa (green) and DS-Red-K-Ras V12/A38 (red). After 24 h, cells were serum starved for 2 h, seeded for 1 h on poly-L-lysine, anti-CD3 plus anti-SLAM, or anti-CD3 plus antiCD28 agonistic Ab (10 mg/ml each)-coated glass-bottom dishes, and images were acquired. Representative images are shown together with a quantification from three independent experiments. *p , 0.05, t test versus control. Scale bar, 5 mm. The histogram shows data from three independent experiments as mean 6 SE (*p , 0.05, t test). C, Control shRNA Jurkat or SAP shRNA Jurkat cells were stimulated with 1 mg/ml anti-CD3 and 0.1 mg/ml anti-CD28 Abs in the presence or in absence of 1 mM R59949. After 15 min, cells were lysed and Ras-GTP was separated by pull-down with Raf-RBD and quantified by Western blotting with anti pan-Ras Ab. Total Ras, phospho-ERK1/2, and SAP contents were revealed in whole-cell lysates by Western blotting. D, Jurkat control-shRNA and Jurkat SAP-shRNA cells were transfected with a Dual-Luciferase NF-AT reporter system. After 48 h, cells were stimulated with 1 mg/ml anti-CD3 and anti-CD28 Abs in the presence or absence of 1 mM R59949. After 16 h stimulation, cells were lysed and analyzed for NF-AT-driven luciferase activity. Graph shows the mean 6 SE of quadruplicates of a representative experiment. *p , 0.05, t test versus control. E, Jurkat control-shRNA or Jurkat SAP-shRNA cells were transfected with a siRNA targeting DGKa or a control siRNA and a Dual-Luciferase NF-AT reporter system. After 48 h, cells were stimulated with 1 mg/ml anti-CD3 and anti-CD28 Abs. After 16 h stimulation, cells were lysed and analyzed for NF-AT-driven luciferase activity. Graph shows the mean 6 SE of quadruplicates of a representative experiment. *p , 0.05, t test versus control. F, Jurkat control-shRNA or Jurkat SAP-shRNA cells were stimulated with 1 mg/ml anti-CD3 and 0.1 mg/ml anti-CD28 Abs. After 72 h, cells were lysed and the amount of IL-2 released in the medium was measured by ELISA. Graph shows the mean 6 SE of four replicates of a representative experiment. *p , 0.05, t test versus control.
for its exit from the nucleus, indicates that enzymatic activity and localization of DGKa are regulated independently of each other, as suggested also by the different kinetics of the two processes. Importantly, these findings also indicate that DGKa exit from the nucleus is not required for the inhibition of its enzymatic activity. The massive exit from the nucleus may reflect a potential increase in the availability of DGKa outside the nucleus for control of DAG signaling both at the plasma membrane and at intracellular vesicles. Indeed, several reports indicate a role of DGKs in T cells intracellular trafficking (50, 53, 54) . Conversely, DGKa exit from the nucleus may contribute to regulate nuclear pools of DAG and PA. Indeed, several DGK isoforms have been reported to localize in the nucleus where they contribute to regulate transcription and cell cycle progression (55) .
Previous evidence indicates that SFK-induced phosphorylation of DGKa on tyrosine 335 mediates its activation and membrane localization upon growth factor stimulation of epithelial and large cell lymphoma cells (24, 56) . Moreover, in T cells DGKa phosphorylation by LCK on tyrosine 335 mediates CD3/CD28-induced recruitment of DGKa to the plasma membrane (21) . Surprisingly, in our study pharmacological inhibition of SFKs did not affect either TCR/CD28-induced inhibition of DGKa or its exit from the nucleus, suggesting that both events are independent from SFKmediated tyrosine phosphorylation of DGKa. Conversely, PP2 completely blocks DGKa inhibition and exit from the nucleus induced by CD3/SLAM, as SLAM signaling is dependent on Fyn tyrosine kinase.
The mechanism by which SAP regulates DGKa still remains to be elucidated. Based on the high similarity between the sequences surrounding tyrosine 335 of DGKa and tyrosine 281 of SLAM, we investigated the hypothesis that SAP may regulate DGKa by associating with it in a complex. However, we could not detect any direct or indirect physical interaction between the two proteins, even in a reconstituted association assay in a mammalian twohybrid system. Our data demonstrate that SAP ability to inhibit DGKa requires the interaction with a yet unidentified SH3 domain-containing protein. The finding that inhibition of DGKa is independent of activity by SFKs suggests that the SAP interactor required for DGKa inhibition is not Fyn. The previous observation that SAP overexpression activates Cdc42 signaling by interacting with SH3-containing bPIX and independently of Fyn suggests that DGKa may be regulated by Cdc42-dependent PAK activation. However, the PAK-specific inhibitor IPA-3 did not affect the inhibition of DGKa following TCR/SLAM costimulation (Fig. 3B) . Finally, upon TCR stimulation of Jurkat cells, SAP silencing results in defective tyrosine phosphorylation of several proteins, including LAT and SLP76 (39) . As both LAT and SLP76 regulate PLCg activation (57) , it is possible to speculate that SAP regulates DGKa by controlling PLCg activity. Consistent with this possibility, PLC activity and cytosolic-free calcium are both required for DGKa inhibition and membrane recruitment. However, lack of SAP in T cells of both SAP-null mice and XLP patients does not affect PLCg-mediated intracellular calcium increase (5, 58) . Moreover, cell stimulation with a calcium ionophore and phorbol ester failed to inhibit DGKa activity and to recruit it to the plasma membrane, indicating that activation of PLC is necessary but not sufficient to regulate both enzymatic activity and membrane localization (data not shown). Furthermore, the requirement for PLC activity in regulating DGKa suggests that the two enzymes may act as a bicomponent unit able to finely modulate the extent and the duration of DAG signaling.
In conclusion, our findings suggest that the coordinated, but independent, control of DGKa enzymatic activity and of its localization regulates both its access to DAG and its rate of conversion to PA. Upon T cell stimulation, such a coordinated and complementary mechanism of regulation might finely tune the intensity and the duration of DAG-mediated signaling. Indeed, SAP silencing, by uncoupling TCR/CD28 costimulation from DGKa inhibition, results in the impairment of TCR/CD28-induced DAGmediated signaling, providing further evidence that the SAPmediated negative regulation of DGKa is crucial for the ability of T cells to trigger DAG-mediated responses.
Similar to cAMP signaling, which is triggered by G proteincoupled receptors by reciprocal regulation of both adenylate cyclase and phosphodiesterase activities (59) , the findings presented in this study suggest that TCR/CD28 controls DAG signaling both by means of PLCg activation and DGKa inhibition. Similarly, genetic and biochemical studies in Caenorhabditis elegans motoneurons and murine hepatocytes showed that DAG-mediated signaling is controlled by G protein-coupled receptor-dependent reciprocal regulation of both PLC and DGKu (60) (61) (62) .
In summary, our findings demonstrate that SAP-mediated DGKa inhibition is an early event in TCR signaling, which might be required for efficient T cell activation. The impaired regulation of DGKa activity in SAP-deficient lymphocytes may contribute to their defective TCR-induced responses, suggesting that pharmacological inhibition of DGKa could be useful in the treatment of certain manifestations of XLP.
